Rhumbline Advisers Y M Abs Therapeutics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 68,399 shares of YMAB stock, worth $582,075. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,399

Previous 53,909 26.88%

Holding current value

$582,075

Previous $238,000 29.41%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$3.64 - $5.35 $52,743 - $77,521	14,490 Added 26.88%	68,399 $308,000
Q1 2025 Apr 08, 2025	BUY	$4.43 - $8.17 $10,884 - $20,073	2,457 Added 4.78%	53,909 $259,000
Q4 2024 May 29, 2025	SELL	$7.76 - $15.69 $19,066 - $38,550	-2,457 Reduced 4.56%	51,452 $402,000
Q4 2024 Jan 30, 2025	SELL	$7.76 - $15.69 $6,696 - $13,540	-863 Reduced 1.65%	51,452 $402,000
Q3 2024 Nov 12, 2024	SELL	$9.95 - $15.39 $20,427 - $31,595	-2,053 Reduced 3.78%	52,315 $686,000
Q2 2024 Aug 01, 2024	SELL	$11.6 - $17.25 $9,929 - $14,766	-856 Reduced 1.55%	54,368 $656,000
Q1 2024 May 09, 2024	BUY	$6.57 - $18.69 $7,956 - $22,633	1,211 Added 2.24%	55,224 $897,000
Q4 2023 Feb 08, 2024	SELL	$4.88 - $7.42 $4,265 - $6,485	-874 Reduced 1.59%	54,013 $368,000
Q3 2023 Nov 09, 2023	BUY	$4.86 - $7.23 $10,196 - $15,168	2,098 Added 3.97%	54,887 $299,000
Q2 2023 Aug 08, 2023	BUY	$5.68 - $10.34 $23,600 - $42,962	4,155 Added 8.54%	52,789 $358,000
Q1 2023 May 11, 2023	SELL	$2.83 - $5.11 $325 - $587	-115 Reduced 0.24%	48,634 $244,000
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $5,832 - $29,490	1,944 Added 4.15%	48,749 $238,000
Q3 2022 Nov 10, 2022	BUY	$13.96 - $19.67 $45,984 - $64,792	3,294 Added 7.57%	46,805 $675,000
Q2 2022 Aug 11, 2022	BUY	$8.22 - $15.13 $60,984 - $112,249	7,419 Added 20.56%	43,511 $658,000
Q1 2022 May 12, 2022	SELL	$6.55 - $17.42 $2,128 - $5,661	-325 Reduced 0.89%	36,092 $429,000
Q4 2021 Feb 10, 2022	SELL	$15.51 - $29.31 $9,383 - $17,732	-605 Reduced 1.63%	36,417 $590,000
Q3 2021 Nov 12, 2021	BUY	$27.47 - $37.31 $54,967 - $74,657	2,001 Added 5.71%	37,022 $1.06 Million
Q2 2021 Aug 05, 2021	SELL	$25.45 - $37.64 $17,178 - $25,407	-675 Reduced 1.89%	35,021 $1.18 Million
Q1 2021 May 06, 2021	SELL	$29.16 - $51.96 $81,648 - $145,488	-2,800 Reduced 7.27%	35,696 $1.08 Million
Q4 2020 Feb 10, 2021	BUY	$37.86 - $54.26 $73,486 - $105,318	1,941 Added 5.31%	38,496 $1.91 Million
Q3 2020 Nov 12, 2020	SELL	$35.13 - $43.62 $186,891 - $232,058	-5,320 Reduced 12.7%	36,555 $1.4 Million
Q2 2020 Aug 13, 2020	BUY	$23.66 - $49.53 $327,146 - $684,851	13,827 Added 49.3%	41,875 $1.81 Million
Q1 2020 May 06, 2020	BUY	$14.39 - $35.8 $11,886 - $29,570	826 Added 3.03%	28,048 $732,000
Q4 2019 Feb 05, 2020	BUY	$23.81 - $33.78 $123,073 - $174,608	5,169 Added 23.44%	27,222 $851,000
Q3 2019 Oct 23, 2019	BUY	$21.57 - $31.37 $13,287 - $19,323	616 Added 2.87%	22,053 $575,000
Q2 2019 Aug 14, 2019	BUY	$19.51 - $28.31 $418,235 - $606,881	21,437 New	21,437 $490,000

Others Institutions Holding YMAB

# of Institutions

Shares Held

26M

Call Options Held

24K

Put Options Held

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $372M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Y M Abs Therapeutics, Inc. Transaction History